Radapex

Insufficiently controlled type 2 DM in adults & childn ≥10 yr as adjunct to diet & exercise: As monotherapy when metformin is considered inappropriate due to intolerance; in addition to other medicinal product for the treatment of type 2 DM. Symptomatic chronic heart failure w/ reduced ejection fraction in adults. CKD in adults.

10 mg once daily. Patient w/ severe hepatic impairment Initially 5 mg, may be increased to 10 mg if tolerated.

May be taken with or without food: Take at any time of the day. Swallow whole.

Hypersensitivity.

Immediately stop treatment if diabetic ketoacidosis is suspected or diagnosed. Temporary interruption of treatment is recommended for patients who develop vol depletion until the depletion is corrected. Caution in patients for whom dapagliflozin-induced drop in BP could pose a risk (eg, patients on antihypertensive therapy w/ history of hypotension or elderly). Monitor vol status (eg, physical exam, BP measurements, lab tests including haematocrit & electrolytes) in case of intercurrent conditions that may lead to vol depletion (eg, GI illness). Not recommended to initiate treatment in patients w/ eGFR <15 mL/min/1.73 m². Glucose-lowering efficacy is reduced when eGFR is <45 mL/min/1.73 m² & is likely absent in patients w/ severe renal impairment. Increased exposure in patients w/ severe hepatic impairment.

Antidiabetic Agents

A10BK01 - dapagliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.

Rx